Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Shares of Gilead Sciences Inc. GILD shed 1.67% to $90.59 Monday, on what proved to be an all-around dismal trading session ...

At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Mizuho Securities analyst Salim Syed has assigned their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...

Alonzo Liñán, Keller’s public works director, said at the Keller City Council meeting Dec. 9 that the design of the Mt.

Gilead isn’t the only Big Pharma to take an interest in Tubulis’ ADC tech. BMS paid the company $23 million upfront in April ...

Mount Gilead held off Ridgedale 59-58 in Ridgedale's home and season opener for boys basketball Wednesday night.